BOADICEA V5’s newest version includes the effects of pathogenic variants (PVs), not restricted to BRCA1 and BRCA2 genes but also in PALB2, CHEK2, ATM, and BARD1 for the breast cancer model and RAD51D, RAD51C, and BRIP1 for the ovarian cancer model [23,25]. This evidence concerns the gene BRCA2 and breast carcinoma.